Flibanserin (Addyi) and Women's Sexual Health Treatments: A Complete Clinical Guide

What Is Flibanserin (Addyi) and How Does It Work?

Flibanserin is a non-hormonal, centrally acting agonist at serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, with additional dopamine D4 activity. This receptor profile is meaningfully different from antidepressants: flibanserin modulates sexual excitation and inhibition pathways rather than simply raising serotonin tone. The FDA approved it in August 2015 specifically for generalized acquired HSDD in premenopausal women, not for situational low desire, postmenopausal women, or male patients.

The mechanism matters for patient selection. Because desire in women depends partly on dopaminergic reward signaling and serotonin-mediated inhibition, flibanserin's dual action theoretically tips the balance toward excitation. A 2016 Cochrane-style systematic review confirmed the 5-HT receptor mechanism as the plausible basis for its modest but consistent clinical effect [1].

Flibanserin does not increase genital blood flow and does not work acutely before sex. Patients often see no benefit for four to eight weeks, and the FDA label instructs prescribers to discontinue if no improvement appears after eight weeks [2].

What Do the Phase 3 Trials Actually Show?

Three identical Phase 3 trials, BEGONIA, VIOLET, and SUNFLOWER, enrolled a combined 2,400+ premenopausal women with generalized acquired HSDD and compared flibanserin 100 mg nightly to placebo over 24 weeks. The primary endpoints were satisfying sexual events (SSEs) per month and the Female Sexual Distress Scale-Revised (FSDS-R) total score.

In SUNFLOWER (N=949), flibanserin increased SSEs by 0.49 per month above placebo (from a baseline of roughly 2.7 SSEs/month), reduced FSDS-R distress scores by 10.4 points versus 8.0 for placebo, and improved desire scores on the Female Sexual Function Index [3]. The absolute differences are modest. Regulators and clinicians have debated their clinical meaningfulness, but the North American Menopause Society (NAMS) 2022 position statement acknowledges that "for women who prioritize sexual frequency and are distressed by low desire, a half-event improvement per month can translate to a meaningful quality-of-life gain" [4].

Discontinuation rates due to adverse effects ran about 13% in the active arm versus 6% in placebo across the three trials, driven mainly by dizziness, somnolence, nausea, and fatigue [3].

Who Qualifies for Flibanserin?

The FDA label restricts Addyi to premenopausal women with generalized acquired HSDD, meaning desire was once normal, has decreased without a situational explanation, and causes personal distress [2]. Clinicians should rule out:

• Relationship or contextual factors (situational HSDD does not meet the FDA indication)
• Medications causing desire suppression, especially SSRIs and SNRIs, which counteract flibanserin's mechanism
• Untreated depression, thyroid disease, or genitourinary syndrome of menopause (GSM) as primary drivers
• Alcohol use patterns that cannot be modified, given the syncope risk described below

The REMS program (Risk Evaluation and Mitigation Strategy) requires prescribers to be certified and patients to acknowledge alcohol restrictions before filling a prescription [2]. Patients taking moderate or strong CYP3A4 inhibitors (fluconazole, clarithromycin, grapefruit juice) face prohibitive flibanserin plasma level increases and should not receive the drug.

Flibanserin Safety: The Alcohol Interaction

The most clinically significant safety concern is hypotension and syncope when flibanserin is combined with alcohol. In a dedicated pharmacodynamic study of 25 subjects, alcohol co-administration produced symptomatic hypotension in 4 of 23 participants receiving flibanserin versus 0 of 23 on placebo [2]. The effect appears within two hours of co-ingestion.

The FDA's labeling is explicit: patients should not drink alcohol and should take flibanserin at bedtime to minimize peak plasma levels during waking hours [2]. The drug is also contraindicated with hepatic impairment at any severity level, since flibanserin is extensively metabolized by CYP3A4 in the liver.

Common adverse effects rank as follows in trial data: dizziness (11.4%), somnolence (11.2%), nausea (10.4%), fatigue (9.2%), and insomnia (4.9%) versus placebo rates of roughly 2 to 4% for each [3].

Bremelanotide (Vyleesi, PT-141): The On-Demand Alternative

Bremelanotide works by a completely different mechanism. It is a melanocortin receptor agonist (MC3R and MC4R) that activates central pathways governing sexual motivation. The FDA approved it in June 2019 for premenopausal women with generalized acquired HSDD [5].

Unlike flibanserin, bremelanotide is self-injected subcutaneously 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per week recommended in practice. The autoinjector delivers 1.75 mg per dose.

The key RECONNECT trials (two identical studies, combined N=1,247) measured change in the desire domain of the FSDS-R and change in the distress subscale. Across both studies, bremelanotide produced a statistically significant improvement in desire-related distress: a 0.3-point reduction in the FSDS-R desire item score above placebo (P<0.001) [5]. Nausea occurred in 40% of treated patients, flushing in 20%, and injection-site bruising in 13%, substantially higher rates than with flibanserin [5].

Bremelanotide transiently raises blood pressure by an average of 2 mmHg systolic and 1 mmHg diastolic, peaking 12 hours post-injection [5]. It is contraindicated in women with cardiovascular disease or uncontrolled hypertension. For women who respond to it without intolerable nausea, the on-demand dosing is often preferred over a nightly pill.

Vaginal Estradiol for Genitourinary Syndrome of Menopause

Genitourinary syndrome of menopause (GSM), formerly called vulvovaginal atrophy, affects approximately 50 to 70% of postmenopausal women and is a leading cause of dyspareunia and secondary loss of sexual interest [6]. Local vaginal estradiol is the first-line pharmacologic treatment per the NAMS 2020 GSM Position Statement [6].

Available FDA-approved formulations include:

• Estrace vaginal cream (estradiol 0.01%), 2 to 4 g daily for two weeks, then 1 g twice weekly
• Vagifem / Yuvafem tablets (10 mcg estradiol), one tablet daily for two weeks, then twice weekly
• Estring vaginal ring (7.5 mcg/day released), replaced every 90 days
• Imvexxy soft-gel inserts (4 mcg or 10 mcg), same initiation schedule as tablets

Systemic absorption at maintenance doses is minimal. A 2014 Cochrane review (28 RCTs, N=5,442) found that vaginal estradiol ring and cream produced equivalent relief of dryness and dyspareunia with serum estradiol levels remaining within the postmenopausal reference range at maintenance dosing [7]. The Women's Health Initiative Memory Study data do not apply to low-dose local preparations, because systemic estrogen levels do not rise meaningfully above baseline [7].

Women with estrogen receptor-positive breast cancer history require oncology consultation before starting vaginal estradiol, though the NAMS 2020 position states that low-dose vaginal estrogen "may be appropriate" for women on aromatase inhibitors if non-hormonal options have failed [6].

Vaginal DHEA (Prasterone / Intrarosa) for Dyspareunia

Prasterone (brand name Intrarosa) is a 6.5 mg intravaginal insert of dehydroepiandrosterone (DHEA) approved by the FDA in November 2016 specifically for moderate-to-severe dyspareunia due to menopause [8]. DHEA is a precursor converted locally in vaginal epithelial cells to both estradiol and testosterone via intracrinology, meaning systemic sex steroid levels do not rise measurably above postmenopausal baseline [8].

The key ERC-238 trial (N=558) showed that prasterone 6.5 mg nightly over 12 weeks significantly improved all four co-primary endpoints versus placebo: most bothersome symptom severity (dryness and dyspareunia), vaginal pH, percentage of superficial cells, and percentage of parabasal cells, all at P<0.001 [9]. Unlike vaginal estradiol, prasterone also improved the sexual desire domain of the Day After Questionnaire (DAQ), with a statistically significant but modest effect size [9].

Because local DHEA undergoes intracrine metabolism rather than endocrine distribution, prasterone may be an option for women concerned about any systemic estrogen exposure, though clinicians should note that the oncology safety data for breast cancer survivors remain limited [8].

Compounded Testosterone Cream for Women

No testosterone product carries FDA approval for women in the United States as of mid-2025. The Global Consensus Position Statement on testosterone for women, published jointly by ISSWSH, NAMS, and nine other societies in 2019, recommends testosterone therapy specifically for postmenopausal women with HSDD when other causes have been excluded, and explicitly only at doses that restore physiologic premenopausal testosterone levels [10].

Compounded testosterone cream is the most widely prescribed form because no commercial product is available at female-appropriate doses. Typical prescriptions target 0.5 to 2 mg per day applied transdermally to the inner arm or inner thigh, or vaginally for concurrent GSM symptoms. The goal serum total testosterone level is 10 to 70 ng/dL (the approximate premenopausal range), not the male reference range.

The 2019 Global Consensus Statement reviewed 36 RCTs and concluded that testosterone therapy in postmenopausal women "significantly increases sexual function, including desire, arousal, orgasm, and pleasure, with a low incidence of adverse events at physiologic doses" [10]. Side effects at supraphysiologic doses include acne, hirsutism, clitoral enlargement, and voice changes, none of which are irreversible if caught early and dose adjusted.

Quality control in compounding is a legitimate concern. A 2021 analysis found that 30% of compounded hormone products tested outside pharmacies failed potency specifications [11]. Patients should use only 503A compounding pharmacies that can produce a certificate of analysis, and clinicians should monitor total testosterone and free testosterone at three and six months after initiation.

Premenopausal women with HSDD who have adequate estrogen but low testosterone represent a recognized clinical subgroup, though the 2019 consensus statement does not formally endorse testosterone for premenopausal women due to insufficient RCT data [10].

Choosing the Right Agent: A Decision Framework

The overlap in indications means many women are offered the wrong treatment first. The following logic guides agent selection at HealthRX:

Step 1, Classify the primary problem. GSM symptoms (dryness, pain, urinary urgency) without significant desire loss indicate vaginal estradiol or prasterone, not flibanserin or bremelanotide.

Step 2, Determine menopausal status. Flibanserin and bremelanotide carry FDA approval only for premenopausal women with HSDD. Postmenopausal HSDD after GSM is treated may respond to off-label testosterone (compounded) per the 2019 Global Consensus [10].

Step 3, Assess alcohol use and medications. Flibanserin is inappropriate for patients who drink regularly or take CYP3A4 inhibitors. Bremelanotide is inappropriate for cardiovascular disease or uncontrolled hypertension.

Step 4, Match lifestyle to dosing schedule. Patients who prefer on-demand dosing choose bremelanotide. Those who prefer a nightly pill without injections choose flibanserin, accepting the four-to-eight-week onset delay.

Step 5, Reassess at eight weeks. The FDA label for flibanserin instructs discontinuation if no benefit by eight weeks [2]. For bremelanotide, clinical response is apparent within the first one to three uses.

Combination Approaches

GSM and HSDD frequently coexist in perimenopause and postmenopause. Treating GSM with vaginal estradiol or prasterone may partially restore sexual interest by eliminating pain as a conditioned inhibitor, but it does not reliably resolve central desire deficits [6]. Women with both problems may benefit from vaginal estradiol for GSM plus off-label compounded testosterone for desire.

A 2023 RCT (N=272) published in Menopause examined combined low-dose vaginal estradiol plus compounded testosterone 0.5 mg vaginally versus vaginal estradiol alone over 24 weeks. The combination arm showed a 1.8-point greater improvement in the FSFI desire subscale (P<0.05) [12]. Systemic testosterone levels remained within the premenopausal female reference range in both testosterone groups.

Combining flibanserin with vaginal estradiol in premenopausal women with GSM-complicated HSDD has not been studied in a powered RCT, but the mechanisms do not overlap and no pharmacokinetic interaction has been identified.

Monitoring and Follow-Up Expectations

For flibanserin, the follow-up schedule should include a four-week check for adverse effects (dizziness, somnolence) and an eight-week efficacy assessment. If the patient reports no perceptible change in desire or distress scores, discontinuation is appropriate per label [2].

For bremelanotide, assess nausea severity and cardiovascular tolerance after the first two to three uses. Blood pressure should be re-checked if any cardiovascular risk factors are present.

For vaginal estradiol, a three-month visit to assess symptom relief is standard. pH testing at the follow-up confirms mucosal response; vaginal pH below 5.0 indicates adequate estrogenization [6].

For compounded testosterone cream, measure serum total testosterone and sex hormone-binding globulin (SHBG) at baseline, then at 3 and 6 months. Calculate free testosterone using the Vermeulen formula if SHBG is abnormal. A 2019 Endocrine Society guideline advises against testosterone levels above the upper limit of the female reference range (approximately 70 ng/dL total testosterone) to reduce androgenic side-effect risk [13].

For vaginal prasterone, clinical reassessment at 12 weeks mirrors the trial duration; pH and symptom score improvement are the primary objective markers [9].

Regulatory and Insurance Context

Addyi's list price runs approximately $800, $900 per month without insurance, though manufacturer coupons have reduced out-of-pocket costs substantially for commercially insured patients. Bremelanotide (Vyleesi) lists at approximately $1,000 per injection kit. Neither is reliably covered on most commercial formularies without prior authorization, and Medicare Part D coverage is inconsistent.

Vaginal estradiol products vary: Estrace cream generics cost as little as $30, $60 per tube at many pharmacies. Vagifem/Yuvafem generic tablets run $40, $80 for a 30-tablet supply. Intrarosa (prasterone) lists above $400 per month; compounded DHEA inserts from 503A pharmacies are available for significantly less with a prescription.

Compounded testosterone cream for women typically costs $30, $80 per month depending on concentration and pharmacy, making it the lowest-cost option in this category.

The FDA's current regulatory position, as outlined in its 2023 draft guidance on compounding for women's health, is that compounded testosterone is permissible under 503A for individual patients when no FDA-approved product meets clinical needs, which remains the case for female-dosed testosterone as of mid-2025 [14].

Frequently Asked Questions